HC Wainwright Predicts Increased Earnings for AngioDynamics

AngioDynamics, Inc. (NASDAQ:ANGO) – HC Wainwright raised their FY2026 earnings per share (EPS) estimates for shares of AngioDynamics in a research note issued to investors on Monday, April 6th. HC Wainwright analyst Y. Chen now forecasts that the medical instruments supplier will post earnings per share of ($0.15) for the year, up from their previous estimate of ($0.28). The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for AngioDynamics’ Q1 2027 earnings at ($0.05) EPS, Q2 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.03) EPS.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.The company had revenue of $78.42 million for the quarter, compared to analyst estimates of $76.77 million.

A number of other equities analysts have also recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, January 21st. Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Freedom Capital raised AngioDynamics to a “strong-buy” rating in a report on Monday. Canaccord Genuity Group decreased their price objective on AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Monday. Finally, Zacks Research downgraded AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.67.

AngioDynamics Stock Performance

Shares of ANGO stock opened at $10.17 on Wednesday. AngioDynamics has a 52-week low of $8.36 and a 52-week high of $13.99. The stock has a market cap of $419.21 million, a price-to-earnings ratio of -13.56 and a beta of 0.43. The firm has a fifty day moving average of $10.83 and a 200-day moving average of $11.53.

Hedge Funds Weigh In On AngioDynamics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANGO. Kotler Kevin acquired a new position in AngioDynamics in the fourth quarter valued at about $21,997,000. Weber Capital Management LLC ADV acquired a new stake in AngioDynamics during the 4th quarter valued at $17,978,000. UBS Group AG increased its holdings in AngioDynamics by 83.6% during the 3rd quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock valued at $12,315,000 after purchasing an additional 501,881 shares in the last quarter. Millennium Management LLC increased its holdings in AngioDynamics by 28.1% during the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after purchasing an additional 393,682 shares in the last quarter. Finally, Nuveen LLC increased its holdings in AngioDynamics by 40.5% during the 4th quarter. Nuveen LLC now owns 1,295,072 shares of the medical instruments supplier’s stock valued at $16,629,000 after purchasing an additional 373,110 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

More AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Freedom Broker initiated coverage with a Buy recommendation, providing fresh buy-side attention that can lift demand for the shares. Freedom Broker initiates coverage of AngioDynamics (ANGO) with buy recommendation
• Positive Sentiment: Zacks upgraded ANGO to a Rank #2 (Buy), signaling growing optimism on earnings prospects and potentially drawing momentum investors. AngioDynamics (ANGO) Upgraded to Buy: Here’s Why
• Positive Sentiment: Freedom Capital (reported via Zacks reference) upgraded to “strong-buy,” adding to the cluster of bullish broker views that can support higher multiple re‑rating. Zacks.com
• Positive Sentiment: HC Wainwright raised several near‑term and FY2026/FY2027 EPS forecasts across multiple quarters (Q1/Q2/Q3/Q4 2027 and FY2026/FY2027), narrowing losses and showing improving profitability trends — this is a key fundamental driver behind the bullish sentiment. MarketBeat – AngioDynamics analyst estimate updates
• Negative Sentiment: Canaccord Genuity cut its price target to $16.00 — while still above the current share price, the downgrade in target could temper upside expectations for some investors. Canaccord Genuity Lowers AngioDynamics Price Target to $16.00

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.